Slideset
View More
MACE and VTE data were presented for all approved and phase III JAK inhibitors.
Here’s how new strategies like ultralow-dose rituximab, a novel small molecule IRAK-4 inhibitor, and vagus nerve stimulation may or may not change clinical practice.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.